MY130551A - Preparation of stable zinc insulin analog crystals - Google Patents

Preparation of stable zinc insulin analog crystals

Info

Publication number
MY130551A
MY130551A MYPI95001263A MYPI9501263A MY130551A MY 130551 A MY130551 A MY 130551A MY PI95001263 A MYPI95001263 A MY PI95001263A MY PI9501263 A MYPI9501263 A MY PI9501263A MY 130551 A MY130551 A MY 130551A
Authority
MY
Malaysia
Prior art keywords
preparation
insulin analog
zinc insulin
stable zinc
analog crystals
Prior art date
Application number
MYPI95001263A
Other languages
English (en)
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY130551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY130551A publication Critical patent/MY130551A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI95001263A 1994-06-16 1995-05-12 Preparation of stable zinc insulin analog crystals MY130551A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (1)

Publication Number Publication Date
MY130551A true MY130551A (en) 2007-06-29

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI95001263A MY130551A (en) 1994-06-16 1995-05-12 Preparation of stable zinc insulin analog crystals

Country Status (29)

Country Link
US (1) US5504188A (OSRAM)
EP (1) EP0692489B1 (OSRAM)
JP (1) JP3595607B2 (OSRAM)
KR (1) KR100369951B1 (OSRAM)
CN (1) CN1184234C (OSRAM)
AT (1) ATE233278T1 (OSRAM)
AU (1) AU697794B2 (OSRAM)
BR (1) BR9502798A (OSRAM)
CA (1) CA2151563C (OSRAM)
CO (1) CO4410205A1 (OSRAM)
CZ (1) CZ286066B6 (OSRAM)
DE (1) DE69529708T2 (OSRAM)
DK (1) DK0692489T3 (OSRAM)
ES (1) ES2188637T3 (OSRAM)
FI (1) FI952930L (OSRAM)
HU (1) HUT73495A (OSRAM)
IL (1) IL114152A (OSRAM)
IN (1) IN178919B (OSRAM)
MY (1) MY130551A (OSRAM)
NO (1) NO952334L (OSRAM)
NZ (1) NZ272358A (OSRAM)
PE (1) PE21896A1 (OSRAM)
PL (1) PL180968B1 (OSRAM)
RO (1) RO113529B1 (OSRAM)
RU (1) RU2156257C2 (OSRAM)
SI (1) SI0692489T1 (OSRAM)
TW (1) TW379228B (OSRAM)
YU (1) YU39595A (OSRAM)
ZA (1) ZA954942B (OSRAM)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
WO1998042367A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
EP1028706B1 (en) * 1997-11-12 2003-07-09 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
CN1210058C (zh) * 1998-10-16 2005-07-13 诺沃挪第克公司 用于肺送递的稳定的浓缩胰岛素制剂
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DK1121145T3 (da) * 1998-10-16 2002-08-12 Novo Nordisk As Insulinpræparater til indgivelse via lungerne, som indeholder mentol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
DE60217066D1 (de) * 2001-02-09 2007-02-08 Genentech Inc Kristallisierung von igf-1
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
BRPI0416743A (pt) 2003-11-20 2007-01-16 Novo Nordisk As formulação farmacêutica, e, métodos de preparar uma formulação de peptìdeo apropriada para uso em um dispositivo de injeção, para reduzir depósitos em equipamento de produção e no produto final, e para reduzir o entupimento de dispositivos de injeção por uma formulação de peptìdeo
JP5220410B2 (ja) 2004-07-19 2013-06-26 バイオコン・リミテッド インスリン−オリゴマー複合体、その処方物及び使用
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
PL1951658T3 (pl) 2005-11-17 2013-02-28 Lilly Co Eli Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
MX2008011123A (es) 2006-03-28 2008-09-30 High Point Pharmaceuticals Llc Benzotiazoles que tienen actividad de receptor h3 de histamina.
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101432262B (zh) 2006-04-24 2011-06-01 伊莱利利公司 作为11-β-羟类固醇脱氢酶1的抑制剂的环己基取代的吡咯烷酮类
MX2008014766A (es) 2006-05-29 2009-03-06 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)-piperazi na, sus sales y solvatos y su uso como antagonista del receptor de h3 histamina.
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
WO2008145732A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
MX2010003979A (es) * 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
EA020496B1 (ru) 2008-11-21 2014-11-28 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
NZ594248A (en) 2009-01-28 2015-03-27 Smartcells Inc Conjugate based systems for controlled drug delivery
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
PT2464655T (pt) * 2009-08-11 2017-05-25 Biocon Ltd Processos cromatográficos
WO2012104339A1 (en) 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
EP3077414B1 (en) 2013-12-04 2020-06-17 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
JP2023520049A (ja) 2020-03-31 2023-05-15 プロトマー・テクノロジーズ・インコーポレイテッド 隣接ジオールに対する選択的応答性のためのコンジュゲート
AU2021382599A1 (en) 2020-11-19 2023-06-22 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE533298A (OSRAM) *
BE515508A (OSRAM) *
BE533252A (OSRAM) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
JPH03506023A (ja) * 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
FI913037A0 (fi) * 1988-12-23 1991-06-20 Novo Nordisk As Humana insulinanaloger.
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
CZ154195A3 (en) 1996-02-14
CN1184234C (zh) 2005-01-12
PL309099A1 (en) 1995-12-27
AU2168195A (en) 1996-01-04
BR9502798A (pt) 1996-06-04
CA2151563A1 (en) 1995-12-17
RU95110107A (ru) 1997-05-10
RO113529B1 (ro) 1998-08-28
NZ272358A (en) 1996-12-20
FI952930A0 (fi) 1995-06-14
DE69529708T2 (de) 2003-10-16
AU697794B2 (en) 1998-10-15
FI952930A7 (fi) 1995-12-17
CZ286066B6 (cs) 2000-01-12
IL114152A0 (en) 1995-10-31
CO4410205A1 (es) 1997-01-09
KR960000922A (ko) 1996-01-25
TW379228B (en) 2000-01-11
ZA954942B (en) 1996-12-17
IN178919B (OSRAM) 1997-07-19
EP0692489A1 (en) 1996-01-17
JP3595607B2 (ja) 2004-12-02
DK0692489T3 (da) 2003-03-31
EP0692489B1 (en) 2003-02-26
CN1128271A (zh) 1996-08-07
KR100369951B1 (ko) 2003-03-28
DE69529708D1 (de) 2003-04-03
ATE233278T1 (de) 2003-03-15
CA2151563C (en) 2007-08-07
NO952334D0 (no) 1995-06-13
JPH08169899A (ja) 1996-07-02
YU39595A (sh) 1997-08-22
SI0692489T1 (en) 2003-06-30
HU9501715D0 (en) 1995-08-28
IL114152A (en) 1999-12-31
FI952930L (fi) 1995-12-17
PE21896A1 (es) 1996-06-15
ES2188637T3 (es) 2003-07-01
HUT73495A (en) 1996-08-28
PL180968B1 (pl) 2001-05-31
NO952334L (no) 1995-12-18
RU2156257C2 (ru) 2000-09-20
US5504188A (en) 1996-04-02

Similar Documents

Publication Publication Date Title
MY130551A (en) Preparation of stable zinc insulin analog crystals
TW326394B (en) Insulin formulation
AU3067995A (en) Method for treatment of sleep apnea
HUT46363A (en) Process for transforming human insulin-precursor into human insulin
AU4938490A (en) Process for production and purification of lactic acid
EP0709395A3 (en) Preparation of Stable Insulin Analog Crystals
HUT51596A (en) Process for production of the active substance of the medical composition levodopa
AU1474788A (en) Crystalline human proinsulin and process for its production
AU2851692A (en) Production of human parathyroid hormone from microorganisms
HU9700060D0 (en) New compound, it's production and it's use as active component of a medicine
AU8113294A (en) Treatment of a patient prior to transplantation
AU3094289A (en) Treatment of abnormal bone conditions using interleukin-6
HUT48278A (en) Process for production of rhenin-hindering dipeptides and medical preparatives containing them
AU4553593A (en) Treatment of diabetes using phosphorylated insulin
AU4807390A (en) Novel fitted dental prosthesis and process for the manufacture thereof
GB2230443B (en) Treatment of sleep apnoea
RO102987B1 (ro) Procedeu de purificare a insulinei
GB9005050D0 (en) Treatment of diabetes
AU8225091A (en) Treatment of a microbial infection with drugs containing para-acetamidobenzoic acid
AU2666084A (en) Activated carbon treatment of plant cultivation
EP0417033A3 (en) Production of dehydrosine fungin by microorganisms and agricultural use
HUT69379A (en) Dermal and transdermal preparation and process for production of it
CA2177595A1 (en) Metallic implant and process for treating a metallic implant
CS72888A1 (en) Method of pentaerythritol's reaction solutions treatment
HU906330D0 (en) Process for the production of external medical preparations containing aluminium-zinc-calium salt dispersion and venom as active agents